Janssen Gains FDA Approval for Inlexzo Intravesical System in Bladder Cancer

Manufacturers producing combination drug-device systems now have a live commercial precedent to benchmark against: Janssen Biotech received FDA approval on September 9, 2025 for gemcitabine intravesical system (Inlexzo) in adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. The product is co-packaged with a urinary catheter and stylet, placing it squarely within the dual-oversight framework that spans both CDER drug regulation and device requirements.

Efficacy data came from Cohort 2 of the SunRISe-1 trial (NCT04640623), a single-arm, multi-center study enrolling 83 patients following transurethral resection. The complete response rate reached 82% (95% CI: 72, 90), with 51% of responders sustaining a duration of response of 12 months or longer. Tumor status was confirmed through cystoscopy, urine cytology, and mandatory biopsies at 24 and 48 weeks, with central pathology review underpinning each CR assessment.

The dosing regimen carries direct implications for device-handling SOPs and catheterization protocols at infusion and urology centers: 225 mg of gemcitabine is delivered intravesically with a three-week indwelling period per insertion, administered every three weeks for up to six months (eight doses), then every 12 weeks for up to 18 months (six doses). Prescribing information includes warnings covering perforated bladder risk, delayed cystectomy and metastatic progression, MRI safety, and embryo-fetal toxicity, each of which will require site-level risk communication and staff training documentation.

The application moved through FDA's Real-Time Oncology Review (RTOR) pilot program alongside the Assessment Aid voluntary submission, compressing the review timeline ahead of the full clinical application filing. Inlexzo also carried breakthrough therapy designation and priority review status, reflecting the unmet need in a population that has exhausted BCG-based options.

For QA and regulatory leads at sites handling combination products, the approval reinforces the operational complexity of maintaining GMP-compliant co-packaging lines and device constituent documentation under a single NDA submission structure, a model that will likely see broader adoption as intravesical and implantable drug-device systems advance through oncology pipelines.

The measurable checkpoint now in view is long-term durability: post-marketing data on sustained complete response beyond 18 months will determine how broadly Inlexzo displaces cystectomy referrals in BCG-unresponsive NMIBC management.

Source: FDA Oncology Center of Excellence via FDA.gov Drugs RSS Feed, November 7, 2026.